-

Imperative Care Announces Appointment of Tyler Binney to Board of Directors

Binney brings significant commercial and operational leadership in the global medical technology sector

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. today announced the appointment of Tyler Binney to the company’s Board of Directors, effective immediately.

“At Imperative Care, we are intentional about building a seasoned leadership team that reflects a rich blend of strategic insight, diverse perspectives, and a shared commitment to elevate patient outcomes and expand care,” said Fred Khosravi, CEO and Chairman of Imperative Care. “We’re delighted to welcome Tyler at this significant stage in the company’s growth, as we further expand our impact and advance life-saving innovations for patients afflicted by runaway clot.”

Mr. Binney brings a proven track record of driving growth through strategic leadership and operational expertise. From April 2021 to November 2023, Mr. Binney served as President and Chief Executive Officer and as a member of the Board of Directors at Relievant Medsystems. During his tenure, he scaled the company’s commercial operations and successfully led its acquisition by Boston Scientific for more than $850 million. Prior to Relievant, Mr. Binney was the President and General Manager of Teleflex’s Interventional Urology Business Unit. He also served as Vice President of Sales at NeoTract, where he played a key role in the company’s $1.1 billion acquisition by Teleflex.

Mr. Binney currently serves as Chairman of the Board of iO Urology and a member of the Board of Directors of Intrinsic Therapeutics and ProVerum Medical.

“Imperative Care has taken an expansive patient-centered approach to addressing the scourge of stroke and other devastating vascular diseases,” said Mr. Binney. “I am honored to join the company’s Board of Directors as it focuses on applying operational discipline to expand its commercial presence and bring life-saving technologies to as many patients as possible.”

About Imperative Care, Inc.

Imperative Care is a commercial-stage medical technology company researching, developing and manufacturing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company is addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. https://imperativecare.com.

Contacts

Investor Contact:
Phil Nalbone
Vice President of Corporate Development and Investor Relations
Imperative Care, Inc.
Pnalbone@imperativecare.com

Media Contact:
Jana Chow
Imperative Care, Inc.
925-324-9846
jchow@imperativecare.com

Imperative Care, Inc.


Release Summary
Imperative Care, Inc. today announced the appointment of Tyler Binney to the company’s Board of Directors, effective immediately.
Release Versions

Contacts

Investor Contact:
Phil Nalbone
Vice President of Corporate Development and Investor Relations
Imperative Care, Inc.
Pnalbone@imperativecare.com

Media Contact:
Jana Chow
Imperative Care, Inc.
925-324-9846
jchow@imperativecare.com

More News From Imperative Care, Inc.

Imperative Care Presents Positive Real-World Data from Ischemic Stroke Patients Treated with ADAPT 2.0 Using the Zoom Stroke System

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care announces late-breaking, real-world data from a multi-center review of ischemic stroke patients treated with ADAPT 2.0....

Imperative Care Announces Late-Breaking Data Presentation and Peer-Reviewed Publication from Pivotal Trial of Symphony Thrombectomy System in Patients with Acute Pulmonary Embolism

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. announces positive results from the SYMPHONY-PE Trial evaluating Symphony® Thrombectomy System in the treatment of acute PE....

Imperative Care Announces FDA Clearance of Symphony Thrombectomy System, the First Large-Bore Continuous Vacuum System for Treatment of Pulmonary Embolism

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. announces FDA 510(k) clearance of its Symphony® Thrombectomy System to treat pulmonary embolism (PE)....
Back to Newsroom